FDA Meeting Consulting Services

FDA meetings are finite opportunities to clarify expectations before you lock development plans. Pre-IND, Type A/B/C, End-of-Phase, pre-NDA/BLA, and device Q-Subs each have different purposes, briefing packages, and follow-up disciplines. Poorly framed questions or an inconsistent story across functions waste the meeting and can leave you with ambiguous minutes that create more internal debate than clarity for the next protocol or CMC campaign.

Viltis supports meeting consulting from objective setting through post-meeting action plans. We help you define what you need from FDA, draft briefing documents that present data honestly and completely, and rehearse SME responses so clinical, CMC, nonclinical, and quality voices stay aligned. Our focus is on questions that resolve real decisions: study design, endpoints, manufacturing controls, device testing, or labeling concepts that affect the next six to eighteen months of spend and timeline.

Preparation also covers logistics and governance: who speaks, how you handle on-the-spot asks, and how you capture commitments. After the meeting we help translate minutes into program changes, protocol amendments, or additional analyses so feedback does not sit unused in a shared drive. When FDA requests follow-up information, we help you respond with the same discipline you used going into the meeting.

Teams often underinvest in rehearsal. A dry run that surfaces conflicting answers between CMC and clinical is more valuable than another polish pass on the slide deck. We run those sessions with the same seriousness as the Agency meeting itself, including how you will handle questions you cannot answer on the spot. We also help you decide whether a written response pathway or a face-to-face meeting better fits the uncertainty you need resolved, so you do not burn a meeting slot on questions that could have been handled in correspondence.

FDA meeting consulting often covers

• Meeting type selection and timing relative to development gates
• Briefing document structure, claims discipline, and appendix control
• Focused question drafting tied to decision points
• Internal dry runs and SME coaching for consistent messaging
• Attendance planning and roles for sponsor and consultant teams
• Post-meeting minutes review and action tracking
• Follow-up correspondence when FDA requests additional information

Strong meeting work reduces rework later. Viltis helps you walk into FDA interactions with a clear ask, a coherent evidence story, and a concrete plan to act on what you hear within days, not quarters.